Denali Therapeutics Future Growth
Future criteria checks 2/6
Denali Therapeutics is forecast to grow earnings and revenue by 27.8% and 58.3% per annum respectively. EPS is expected to grow by 30.1% per annum. Return on equity is forecast to be -35.5% in 3 years.
Key information
27.8%
Earnings growth rate
30.1%
EPS growth rate
Biotechs earnings growth | 28.8% |
Revenue growth rate | 58.3% |
Future return on equity | -35.5% |
Analyst coverage | Good |
Last updated | 04 Oct 2024 |
Recent future growth updates
Recent updates
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Just Slashed This Year's Estimates
Mar 07Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 252 | -387 | -290 | -251 | 9 |
12/31/2025 | 69 | -454 | -437 | -285 | 13 |
12/31/2024 | 23 | -416 | -525 | -323 | 14 |
6/30/2024 | 1 | -420 | -402 | -391 | N/A |
3/31/2024 | 295 | -137 | -425 | -413 | N/A |
12/31/2023 | 331 | -145 | -371 | -358 | N/A |
9/30/2023 | 341 | -124 | -348 | -332 | N/A |
6/30/2023 | 343 | -128 | -321 | -302 | N/A |
3/31/2023 | 101 | -371 | -248 | -231 | N/A |
12/31/2022 | 108 | -326 | -263 | -245 | N/A |
9/30/2022 | 111 | -303 | -254 | -238 | N/A |
6/30/2022 | 112 | -284 | -234 | -222 | N/A |
3/31/2022 | 83 | -286 | -243 | -233 | N/A |
12/31/2021 | 49 | -291 | -220 | -211 | N/A |
9/30/2021 | 353 | 30 | 361 | 368 | N/A |
6/30/2021 | 357 | 56 | 404 | 410 | N/A |
3/31/2021 | 340 | 58 | 415 | 420 | N/A |
12/31/2020 | 336 | 71 | 413 | 416 | N/A |
9/30/2020 | 24 | -228 | -150 | -145 | N/A |
6/30/2020 | 28 | -216 | -183 | -176 | N/A |
3/31/2020 | 26 | -215 | -193 | -176 | N/A |
12/31/2019 | 27 | -198 | -169 | -152 | N/A |
9/30/2019 | 148 | -66 | -27 | -11 | N/A |
6/30/2019 | 135 | -55 | -30 | -15 | N/A |
3/31/2019 | 133 | -52 | -19 | -14 | N/A |
12/31/2018 | 129 | -36 | 47 | 50 | N/A |
9/30/2018 | 3 | -137 | -64 | -61 | N/A |
6/30/2018 | 2 | -123 | -51 | -49 | N/A |
3/31/2018 | 1 | -91 | N/A | -24 | N/A |
12/31/2017 | N/A | -88 | N/A | -77 | N/A |
9/30/2017 | N/A | -85 | N/A | -77 | N/A |
6/30/2017 | N/A | -93 | N/A | -76 | N/A |
3/31/2017 | N/A | -90 | N/A | -75 | N/A |
12/31/2016 | N/A | -87 | N/A | -72 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNLI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNLI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNLI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNLI's revenue (58.3% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: DNLI's revenue (58.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNLI is forecast to be unprofitable in 3 years.